NCT04963764View on ClinicalTrials.gov

Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 18, 2021

Primary Completion Date

May 27, 2022

Study Completion Date

May 27, 2022

Conditions
PneumoniaPediatric Respiratory DiseasesAntibiotic UseCommunity-acquired Pneumonia
Interventions
DRUG

Amoxicillin

Participants will be randomized to receive oral amoxicillin for a standard course (10 days)

DRUG

Placebo

Participants will be randomized to receive oral placebo for a standard course (10 days)

Trial Locations (3)

19104

The Children's Hospital of Philadelphia, Philadelphia

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

60610

Ann & Robert H Lurie Children's Hospital of Chicago, Chicago

All Listed Sponsors
collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

Children's Hospital Medical Center, Cincinnati

OTHER

collaborator

University of Utah

OTHER

lead

Ann & Robert H Lurie Children's Hospital of Chicago

OTHER

NCT04963764 - Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia | Biotech Hunter | Biotech Hunter